FindTrial
Sign In

Effect of pamidronate on bone loss and implant stability after total hip arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN37786144
Enrollment
Unknown
Registered
2003-01-06
Start date
2002-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periprosthetic bone loss after total hip replacement Musculoskeletal Diseases Periprosthetic bone loss

Interventions

Pamidronate sodium as a single 90 mg infusion versus saline infusion given on the 5th day postoperatively after total hip arthroplasty

Sponsors

Arthritis Research Campaign (ARC) (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Men and women undergoing primary total hip arthroplasty for osteoarthritis of the hip.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026